Chantix: no excess cardiovascular risk in new meta-analysis
www.pulmccm.org
(image: People's Pharmacy) Sure to re-light controversy around Pfizer's varenicline (Chantix): a new study concludes the smoking cessation drug likely carries no increased risk for cardiovascular events. Judith Prochaska and Joan Hilton (University of California - San Francisco) report the results in the May 4
Chantix: no excess cardiovascular risk in new meta-analysis
Chantix: no excess cardiovascular risk in new…
Chantix: no excess cardiovascular risk in new meta-analysis
(image: People's Pharmacy) Sure to re-light controversy around Pfizer's varenicline (Chantix): a new study concludes the smoking cessation drug likely carries no increased risk for cardiovascular events. Judith Prochaska and Joan Hilton (University of California - San Francisco) report the results in the May 4